| Recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496 | University of Arizona | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study NCT06079723 | Power Life Sciences Inc. | — |
| Completed | Predictive Factors for Medullary Thyroid Cancer Aggressiveness NCT06292988 | Aristotle University Of Thessaloniki | — |
| Recruiting | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369 | Shanghai Jiao Tong University School of Medicine | N/A |
| Withdrawn | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MT NCT04760288 | Hoffmann-La Roche | Phase 3 |
| Recruiting | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC NCT06277180 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma NCT05830500 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 |
| Unknown | A Study of TY-1091 in Patients With Advanced Solid Tumors NCT05675605 | TYK Medicines, Inc | Phase 1 / Phase 2 |
| Completed | Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer NCT05534594 | University Medical Center Groningen | N/A |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Unknown | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor NCT05278364 | Shouyao Holdings (Beijing) Co. LTD | Phase 1 / Phase 2 |
| Unknown | Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis NCT04760171 | The Leeds Teaching Hospitals NHS Trust | — |
| Active Not Recruiting | Thermal Ablation of Cervical Metastases From Thyroid Carcinoma NCT04522570 | Instituto do Cancer do Estado de São Paulo | N/A |
| Active Not Recruiting | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive NCT04280081 | Eli Lilly and Company | Phase 2 |
| Active Not Recruiting | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer NCT04211337 | Loxo Oncology, Inc. | Phase 3 |
| Terminated | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or M NCT04161391 | Turning Point Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer NCT03838692 | Antonio Fojo | Phase 2 |
| Active Not Recruiting | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nerv NCT03899792 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumo NCT03157128 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With NCT02856347 | Institut Claudius Regaud | N/A |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors NCT02709889 | AbbVie | Phase 1 / Phase 2 |
| Completed | Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients NCT02465424 | Velindre NHS Trust | — |
| Active Not Recruiting | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer NCT01896479 | Exelixis | Phase 4 |
| Terminated | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer NCT02363647 | Icahn School of Medicine at Mount Sinai | N/A |
| Unknown | 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer NCT03643055 | University Medical Centre Ljubljana | — |
| Unknown | Radiolabeled Molecules for Medullary Thyroid Cancer NCT01915485 | Instituto Nacional de Cancer, Brazil | Phase 4 |
| Unknown | The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer NCT01739634 | Salient Pharmaceuticals Incorporated | Phase 1 / Phase 2 |
| Recruiting | Natural History Study of Children and Adults With Medullary Thyroid Cancer NCT01660984 | National Cancer Institute (NCI) | — |
| Completed | Vandetanib Risk Minimisation Effectiveness NCT01757470 | Genzyme, a Sanofi Company | — |
| Completed | SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer NCT01625520 | Federico II University | Phase 2 |
| Completed | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetani NCT01539655 | Sanofi | Phase 1 |
| Completed | Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment NCT01298323 | Sanofi | Phase 3 |
| Terminated | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer NCT00582712 | University of Wisconsin, Madison | Phase 2 |
| Completed | Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcin NCT06243965 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| No Longer Available | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) NCT02174679 | Jonsson Comprehensive Cancer Center | — |
| Approved For Marketing | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation NCT03906331 | Eli Lilly and Company | — |
| Approved For Marketing | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC NCT04204928 | Blueprint Medicines Corporation | — |
| Approved For Marketing | Expanded Access of Cabozantinib in Medullary Thyroid Cancer NCT01683110 | Exelixis | — |